Gingko containing formulations for the improvement of skin radiance

ABSTRACT

This invention relates to topical formulations containing both feverfew extract and  Gingko biloba  extract and the use thereof to increase skin radiance.

CROSS REFERENCE TO RELATED APPLICATION

This application claims priority from application European PatentApplication No. 03293264.2 filed Dec. 19, 2003 which is incorporated byreference herein.

FIELD OF THE INVENTION

This invention relates to topical formulations containing both feverfewextract and Gingko biloba extract and the use thereof to increase skinradiance.

BACKGROUND OF THE INVENTION

The appearance and condition of the skin may be degraded throughexternal factors such as sunlight, exposure to wind and to cool and dryair, air pollutants, smoking, as well as internal factors such asdermatological diseases, age-related hormonal changes or the normalaging process. In particular upon aging, the skin becomes less elasticand develops fine lines and wrinkles. Other phenomena that develop uponaging comprise skin thinning, skin sagging, and age spots appear, andthe skin loses its tone and natural radiance. Specifically the decreaseof skin radiance is attributed to the accumulation of toxins in skincells coming from cell metabolism created by external factors such assunlight or pollution. This creates non-homogeneous color areas in theskin or dull skin. These toxins mainly comprise reactive oxygen species.

To counteract skin degradation and in particular to prevent and levelthe effects of skin-aging, consumers have increasingly sought new and/orimproved cosmetic compositions and cosmetic methods for skin care. Tomeet consumer demand, cosmetic products have been developed for treatingthe effects of skin-aging, which products for example are based onactive ingredients such as vitamin A or its derivatives, alpha-hydroxyacids, vitamin C or plant extracts.

Reduced skin tone and/or skin radiance is one of the elements in theskin-aging process. To counteract this, use has been made of pigments ormakeup, which had a cosmetic (or exterior) effect, which is onlytemporary, but did not interfere with the root cause of the problem. Theuse of certain mineral components that enlarge the blood vessels wasaimed at a more in depth approach of dealing with this problem.

WO-00/74699 discloses the use of compositions containing extracts offeverfew against inflammatory disorders. Particular extracts for thisapplication are extracts that are substantially free of α-unsaturatedγ-lactones.

U.S. Pat. No. 2,002,0182166 discloses a composition for regulating thefirmness, tone or texture of skin, or for regulating wrinkles, or forthe treatment of external aggression in skin containing a safe andeffective amount of feverfew extract and a cosmetically-acceptabletopical carrier, and the use thereof.

Tanacetum parthenium, a plant commonly known as feverfew, has beenrecognized for a long time as having significant medicinal propertieswhen taken orally. Extracts of feverfew contain many components.Although not all components have been isolated and characterized, theknown components of an extract of feverfew contain a significant numberof biologically active components. To date, the chemical constituents ofwhole feverfew extract include, but are not limited to,apigenin-7-glucoside, apigenin-7-glucuronide, 1-β-hydroxyarbusculin,6-hydroxykaempferol-3,7-4′-trimethylether (Tanetin),6-hydroxykaempferol-3,7-dimethyl ether, 8-β-reynosin, 10-epicanin,ascorbic acid, beta-carotene, calcium, chromium, chrysanthemolide,chrysanthemomin, chrysarten-A, chrysarten-c, chrysoeriol-7-glucuronide,cobalt, cosmosiin, epoxyartemorin, luteolin-7-glucoside,luteolin-7-glucuronide, mangnoliolide, parthenolide,quercetagentin-3,7,3,-trimethylether, quercetagetin-3′7-dimethylether,reynosin, tanaparthin, tanaparthin-1α,4α-epoxide,tanaparthin-1β,4β-epoxide, β-costunolide, 3-β-hydroxy-parthenolide, and3,7,3′-trimethoxyquercetagetin.

Ginkgo biloba is a dioecious tree from the Far East, the leaves of whichare used for certain medicinal properties. They contain constituents,such as aliphatic hydrocarbons and alcohols, polyphenols, such asluteolin or quercetol, or biflavones derived from amentaflavone, andmore specific constituents: ginkgolic acid, and anacardic derivatives,terpenes derived from limonene or terpenes containing a tert-butylgroup. They have been used in cosmetology for their protective effectagainst free radicals.

EP-A-0955995 relates to the use of at least two compounds chosen fromcomponents having an a) anti-radical, b) anti-inflammatory and c)anti-allergic activity for the preparation of a composition exhibitingat least two of the a), b) and c) activities intended for the treatmentof sensitive and/or allergic skin, amongst which is Gingko bilobaextract.

EP-A-0877619 relates to the use of at least one active ingredientcapable of being obtained by extraction from Ginkgo biloba for thepreparation of a composition with immunomodulatory activity and furtherrelates to methods for the cosmetic treatment of sensitive skins.

It is an object of this invention to provide formulations that have apositive effect on skin radiance and improve complexion.

The formulations of the present invention containing Gingko biloba,which is an extract that has anti-free radical activity, and feverfewextract, which has anti-inflammatory activity, have been found to have abeneficial effect on skin radiance.

SUMMARY OF THE INVENTION

Thus in one aspect, the present invention concerns a cosmeticformulation containing feverfew extract and Gingko Biloba extract.

In a particular aspect there is provided a cosmetic formulationcontaining

-   (a) from 0.01% to 5% of feverfew extract; and-   (b) from 0.005% to 1% of Gingko biloba extract.

In another aspect, the invention features the use of a cosmeticformulation as specified herein for maintaining or improving skinradiance.

DETAILED DESCRIPTION OF THE INVENTION

As used herein, all percentages are by weight unless otherwisespecified. As used herein the term ‘cosmetic’ relates to applications onthe skin in order to have skin-beneficial effects and is meant to relateto terms such as topical and skin care.

As used herein the term ‘feverfew extract’ is meant to comprise a blendof components isolated from a plant from the Chrysanthemum or Tanacetumgenera (hereinafter referred to as Feverfew). Examples of Feverfewinclude, bur are not limited to, Chrysanthemum parthenium, Tanacetumparthenium, or Matricania parthenium.

Such components may be isolated from a part(s) of the plant (e.g., thearial part of the plant such as the stem, flower, and leaves) byphysically removing a piece of such plant, such as grinding a leaf onthe plant. Such components may also be isolated from the plant by usingextraction procedures well known in the art (e.g., the use of organicsolvents such as C₁-C₈ alcohols, C₁-C₈ alkyl polyols, C₁-C₈ alkylketones, C₁-C₈ alkyl ethers, acetic acid C₁-C₈ alkyl esters, andchloroform, and/or inorganic solvents such as water, inorganic acidssuch as hydrochloric acid, and inorganic bases such as sodiumhydroxide). In one embodiment, the feverfew extract contains onlyhydrophilic components (e.g., isolated by using a hydrophilic solvent,such as water or ethanol). In one embodiment, the Feverfew extractcontains only hydrophobic components (e.g. isolated by using ahydrophobic solvent, such as chloroform). In one embodiment, theFeverfew extract contains both hydrophilic and hydrophobic components.

A particular feverfew extract is that described in WO-00/74699, which isfeverfew extract substantially free of α-unsaturated γ-lactones. Theterm “substantially free of alpha-unsaturated gamma-lactones” refers toan extract of feverfew having a weight content of the α-unsaturatedγ-lactones found in natural feverfew extracts of less than about 0.2% byweight. These α-unsaturated γ-lactones include but are not limited toparthenolide ([1αR-(1a R*, 4E,7a S*, 10a S*, 10bR*)]2,3,4,7,7a,8,10a,10b-octahydro-1a,5-dimethyl-8-4,5α-epoxy-6β-hydroxy-germacra-1(10),11(13)-dien-12-oic acid γ-lactone), 3-β-hydroxy-parthenolide,costunolide, 3-β-constunolide, artemorin, 8-α-hydroxy-estafiatin,chysanthemolide, magnoliolide, tanaparthin, tanaparthin-1α,4α-epoxide,tanaparthin-1β,4β-epoxide, chrysanthemonin, and other sesquiterpenes.Preferably, the feverfew extract has a weight content of below about0.2. Preferably, the feverfew extract has a weight content ofα-unsaturated γ-lactones below about 0.2% by weight. Preferably theα-unsaturated γ-lactone is parthenolide.

Methods for the manufacture of Feverfew extracts that are substantiallyfree of parthenolide and other alpha-unsaturated gamma-lactones aredisclosed in WO-00/74695.

Of interest are formulations with low content of parthenolide. What ismeant by “low content of parthenolide” is that the compositioncomprises, by weight, less than 0.1%, preferably below 0.01%, morepreferably below 0.001% or does not comprise any parthenolide.

Since the α-unsaturated γ-lactones cause some of the allergic reactionsto extracts of feverfew, topical compositions made from α-unsaturatedγ-lactone-deprived extracts are preferred because of theirnon-irritating/non-sensitizing properties.

The Feverfew extract may contain the following compounds:flavanoid/flavone compounds which include, but are not limited to,tanetin, 3,7,3′-trimethoxy quercetagetin, apigenin and its derivatives.When flavanoid/flavone compounds are present, they are present at aconcentration of between about 0.001% to about 0.5% such as betweenabout 0.005% and 0.2% based on the weight of the topical composition.

As used herein the term ‘Gingko biloba extract’ is meant to comprise ablend of components isolated from Gingko biloba. Various Ginkgo bilobaextracts may be suitable for carrying out the invention; preferably, theterpene concentration in these extracts is less than about 7% w/w.Indeed, Ginkgo biloba has a complex chemical composition which comprisesaliphatic alcohols and hydrocarbons, steroids, amino acids, polyphenolssuch as luteolin, quercetol and more specific biflavones derived fromamentaflavone (bilobetin, ginkgetin); it also contains ginkgolic acidand sesquiterpene-chain-containing anacardic derivatives, terpenesderived from limonene and terpenes with tert-butyl groups (bilobalidesand Ginkgolides).

Extracts appropriate for carrying out the invention may have a contentof terpene derivatives with a value of less than about 3% w/w of drymatter, especially of less than 1% w/w and advantageously of less than0.5% w/w. Preferably, chlorophyll, lipids, waxes and lectins aresubstantially removed from the extract used. By preference, the extractalso substantially lacks substances such as ginkgolic acid, biflavonoidsor free aglycones. The concentration of proanthocyanidins is preferablyless than 5% w/w of the dry extract. Extracts that can be used accordingto the invention preferably have a concentration of flavone heterosidesgreater than 24% w/w of dry matter, more preferably greater than 28%w/w; it is advantageously between about 29 and 35% w/w. The flavoneheterosides are compounds whose aglycone is a flavonol such asquercetin, kaempferol or isorhamnetin. These are mono-, tri- andespecially diglucosides, of which the principal carbohydrateconstituents are glucose and rhamnose. They are present in a substantialproportion in the form of coumarin esters of quercetin and of kaempferolglucorhamnoside. A Ginkgo extract which is particularly suitable forcarrying out the invention has a water content of less than 3% w/w, aconcentration of flavone heterosides of 32±3% w/w, a Ginkgolic acidconcentration of less than 10 ppm, a proanthocyanidin concentration ofless than 5% w/w and a terpene concentration of less than 0.5% w/w.Particular extracts for use in this invention, as well as theirpreparation have been described in EP-A-0877619

The extracts may be dry extracts or may be liquid extracts, e.g. inaqueous media. Dry extracts are preferred.

The Fever few extract may be present a at a concentration which can bebetween 0,01% and 5%, in particular between 0.05% and 2%, further inparticular between 0.05 and 1%, e.g. at about 0.1%.

The Ginko biloba extract may be present at a concentration which can bebetween 0,005% and 1%, in particular between 0.01% and 0.05%.

In certain embodiments of the invention, the w/w ratio between the totalamount of Feverfew extracts and the total amount of Gingko bilobaextracts is in the range of from 1000:1 to 1:100; in particular from100:1 to 1:10; more in particular from 10:1 to 1:1.

The formulations in accordance with the invention may additionallycontain other plant extracts. Of particular interest are soy extracts,preferably the soy extracts disclosed in EP-A-1236465. The soy extractscan be present at a concentration, which may be between 0.01% to 5%, inparticular between 0.1% and 3%, preferably between 0.5% and 2%, e.g. ata concentration of about 1%.

The formulations may further contain vitamins such as Vitamin E or aderivative thereof such as tocopherol acetate. The Vitamin E may bepresent at a concentration which can be between 0.01% to 1%, with anoptimal at 0,3%.

The topical formulations of the present invention may comprise theFeverfew extract, the Gingko biloba extract and acosmetically-acceptable topical carrier. In certain embodiments, thecosmetically-acceptable topical carrier is from about 50% to about99.99%, by weight, of the composition (e.g., from about 80% to about95%, by weight, of the composition.

The compositions may be made into a wide variety of product types thatinclude, but are not limited to, lotions, creams, gels, sticks, sprays,shaving creams, ointments, cleansing liquid washes and solid bars,shampoos, pastes, powders, mousses, shaving creams, wipes, patches, naillacquers, wound dressing and adhesive bandages, hydrogels, films andmake-up such as foundations, mascaras, and lipsticks. These producttypes may comprise several types of cosmetically-acceptable topicalcarriers including, but not limited to, solutions, emulsions (e.g.,microemulsions and nanoemulsions), gels, solids and liposomes. Thefollowing are non-limitative examples of such topical carriers. Othertopical carriers can be formulated by those of ordinary skill in theart.

The topical formulations of the present invention can be formulated assolutions. Solutions typically include an aqueous solvent (e.g., fromabout 50% to about 99.99% or from about 90% to about 99% of acosmetically acceptable aqueous solvent).

The topical formulations of the invention may be formulated as asolution comprising an emollient. Such compositions preferably containfrom about 2% to about 50% of an emollient(s). As used herein,“emollients” refer to materials used for the prevention or relief ofdryness, as well as for the protection of the skin. A wide variety ofsuitable emollients are known and may be used herein. The InternationalCosmetic Ingredient Dictionary and Handbook, eds. Wenninger and McEwen,pp. 1656-61, 1626, and 1654-55 (The Cosmetic, Toiletry, and FragranceAssoc., Washington, D.C., 7^(th) Edition, 1997) (hereinafter “ICIHandbook”) contains numerous examples of suitable materials.

A lotion can be made from such a solution. Lotions typically comprisefrom about 1% to about 20% (e.g., from about 5% to about 10%) of anemollient(s) and from about 50% to about 90% (e.g., from about 60% toabout 80%) of water.

Another type of product that may be formulated from a solution is acream. A cream typically comprises from about 5% to about 50% (e.g.,from about 10% to about 20%) of an emollient(s) and from about 45% toabout 85% (e.g., from about 50% to about 75%) of water.

Yet another type of product that may be formulated from a solution is anointment. An ointment may comprise a simple base of animal or vegetableoils or semi-solid hydrocarbons. An ointment may comprise from about 2%to about 10% of an emollient(s) plus from about 0.1% to about 2% of athickening agent(s). A more complete disclosure of thickening agents orviscosity increasing agents useful herein can be found in the ICIHandbook pp. 1693-1697.

The topical formulations useful in the present invention are formulatedas emulsions. If the carrier is an emulsion, from about 1% to about 10%(e.g., from about 2% to about 5%) of the carrier comprises anemulsifier(s). Emulsifiers may be nonionic, anionic or cationic.Suitable emulsifiers are disclosed in, for example, U.S. Pat. Nos.3,755,560, 4,421,769, McCutcheon's Detergents and Emulsifiers, NorthAmerican Edition, pp. 317-324 (1986), and the ICI Handbook, pp.1673-1686.

Lotions and creams can be formulated as emulsions. Typically suchlotions comprise from 0.5% to about 5% of an emulsifier(s). Such creamswould typically comprise from about 1% to about 20% (e.g., from about 5%to about 10%) of an emollient(s); from about 20% to about 80% (e.g.,from 30% to about 70%) of water; and from about 1% to about 10% (e.g.,from about 2% to about 5%) of an emulsifier(s).

Single emulsion skin care preparations, such as lotions and creams, ofthe oil-in-water type and water-in-oil type are well-known in thecosmetic art and are useful in the subject invention. Multiphaseemulsion compositions, such as the water-in-oil-in-water type are alsouseful in the subject invention. In general, such single or multiphaseemulsions contain water, emollients, and emulsifiers as essentialingredients.

The topical formulations of this invention can also be formulated as agel (e.g., an aqueous gel using a suitable gelling agent(s). Suitablegelling agents for aqueous gels include, but are not limited to, naturalgums, acrylic acid and acrylate polymers and copolymers, and cellulosederivatives (e.g., hydroxymethyl cellulose and hydroxypropyl cellulose).Suitable gelling agents for oils (such as mineral oil) include, but arenot limited to, hydrogenated butylene/ethylene/styrene copolymer andhydrogenated ethylene/propylene/styrene copolymer. Such gels typicallycomprises between about 0.1% and 5%, by weight, of such gelling agents.

The topical formulations of the present invention can also be formulatedinto a solid formulation (e.g., a wax-based stick, soap bar formulation,powder, or a wipe containing powder).

Liposomal formulations are also useful formulations of the subjectinvention. Examples of liposomes are unilamellar, multilamellar, andoligolamellar liposomes, which may or may not contain phospholipids.Such compositions can be prepared by first combining hesperetin with aphospholipid, such as dipalmitoylphosphatidyl choline, cholesterol andwater according to art-known methods. Epidermal lipids of suitablecomposition for forming liposomes may be substituted for thephospholipid. The liposome preparation may then be incorporated into oneof the above carriers (e.g., a gel or an oil-in-water emulsion) in orderto produce the liposomal formulation.

The topical formulations useful in the subject invention may contain, inaddition to the aforementioned components, a wide variety of additionaloil-soluble materials and/or water-soluble materials conventionally usedin formulations for use on skin, hair, and nails at theirart-established levels.

In one embodiment, the topical formulation comprises one or morecosmetically active agents. What is meant by a “cosmetically activeagent” is a compound that has a cosmetic or therapeutic effect on theskin, hair, or nails, e.g., lightening agents, darkening agents such asself-tanning agents, anti-acne agents, shine control agents,anti-microbial agents, anti-inflammatory agents, anti-mycotic agents,anti-parasite agents, external analgesics, sunscreens, photoprotectors,antioxidants, keratolytic agents, detergents/surfactants, moisturizers,nutrients, vitamins, energy enhancers, anti-perspiration agents,astringents, deodorants, hair removers, firming agents, anti-callousagents, and agents for hair, nail, and/or skin conditioning.

Examples of cosmetically active agents are hydroxy acids, benzoylperoxide, sulfur resorcinol, ascorbic acid, D-panthenol, hydroquinone,octyl methoxycinnamate, titanium dioxide, octyl salicylate, homosalate,avobenzone, polyphenolics, carotenoids, free radical scavengers, spintraps, retinoids such as retinol and retinyl palmitate, ceramides,polyunsaturated fatty acids, essential fatty acids, enzymes, enzymeinhibitors, minerals, hormones such as estrogens, steroids such ashydrocortisone, 2-dimethylaminoethanol, copper salts such as copperchloride, peptides containing copper such as Cu:Gly-His-Lys, coenzymeQ10, peptides such as those disclosed in WO-00/15188, lipoic acid, aminoacids such a proline and tyrosine, vitamins, lactobionic acid,acetyl-coenzyme A, niacin, riboflavin, thiamin, ribose, electrontransporters such as NADH and FADH2, and other botanical extracts suchas aloe vera and soy, and derivatives and mixtures thereof. Thecosmetically active agent will typically be present in the formulationof the invention in an amount of from about 0.001% to about 20% byweight of the formulation, e.g., about 0.01% to about 10% such as about0.1% to about 5%.

Examples of vitamins include, but are not limited to, vitamin A, vitaminBs such as vitamin B3, vitamin B5, and vitamin B12, vitamin C, vitaminK, and vitamin E and derivatives thereof.

Examples of hydroxy acids include, but are not limited, to glycolicacid, lactic acid, malic acid, salicylic acid, citric acid, and tartaricacid (see, e.g., EP-A-273,202).

Examples of antioxidants include, but are not limited to, water-solubleantioxidants such as sulfhydryl compounds and their derivatives (e.g.,sodium metabisulfite and N-acetyl-cysteine), lipoic acid anddihydrolipoic acid, resveratrol, lactoferrin, and ascorbic acid andascorbic acid derivatives (e.g., ascorbyl palmitate and ascorbylpolypeptide). Oil-soluble antioxidants suitable for use in theformulations of this invention include, but are not limited to,butylated hydroxytoluene, retinoids (e.g., retinol and retinylpalmitate), tocopherols (e.g., tocopherol acetate), tocotrienols, andubiquinone. Natural extracts containing antioxidants suitable for use inthe formulations of this invention, include, but not limited to,extracts containing flavonoids and isoflavonoids and their derivatives(e.g., genistein and diadzein), extracts containing resveratrol and thelike. Examples of such natural extracts include grape seed, green tea,pine bark, and propolis. Other examples of antioxidants may be found onpages 1612-13 of the ICI Handbook.

Various other materials may also be present in the formulations usefulin the subject invention. These include humectants, proteins andpolypeptides, preservatives and an alkaline agent. Examples of suchagents are disclosed in the ICI Handbook, pp. 1650-1667. Theformulations of the present invention may also comprise chelating agents(e.g., EDTA) and preservatives (e.g., parabens). Examples of suitablepreservatives and chelating agents are listed in pp. 1626 and 1654-55 ofthe ICI Handbook. In addition, the topical formulations useful hereincan contain conventional cosmetic adjuvants, such as dyes, opacifiers(e.g., titanium dioxide), pigments and fragrances.

The formulations of the present invention may be prepared using amineral water. In one embodiment, the mineral water has a mineralizationof at least about 200 mg/l (e.g. from about 300 mg/l to about 1000mg/l). In one embodiment, the mineral water comprises at least about 10mg/l of calcium and/or at least about 5 mg/l of magnesium.

The formulations of the invention are for improving skin radiance butmay also be used for regulating one ore more skin-aging factors such asthe firmness, tone or texture of skin, and regulating wrinkles in skin.

As used herein, “regulating the firmness of skin” means the enhancing ofthe firmness or elasticity of the skin, preventing the loss of firmnessor elasticity of skin, or preventing or treating sagging, lax and looseskin. The loss of skin elasticity or firmness may be a result of anumber of factors, including but not limited to aging, environmentaldamage, or the result of an application of a cosmetic to the skin.

As used herein, “regulating the tone of skin” means the lighteningand/or darkening of the skin (e.g., lightening pigmented lesions ordarkening skin sallowness).

As used herein, “regulating the texture of skin” means the smoothing ofthe surface of the skin to remove either bumps or crevasses on the skinsurface.

As used herein, “regulating wrinkles in skin” means preventing,retarding, arresting or reversing the process of wrinkle and fine lineformation in skin. As used herein, “treatment of external aggressions inskin” means the reduction or prevention of the damage from externalaggressions in skin. Examples of external aggressions include, but arenot limited to, damage to the skin from the use of cleansers (e.g.,topical cleansers containing surfactants), make-up, shaving as well asenvironmental damage such as from UV light (e.g., sun-damage fromsunlight or damage from non-natural sources such as UV lamps and solarsimulators), ozone, exhaust, pollution, chlorine and chlorine containingcompounds and cigarette smoke. Effects of external aggressions on theskin include, but are not limited to, oxidative and/or nitrosativedamage to and modifications on lipids, carbohydrates, peptides,proteins, nucleic acids, and vitamins. Effects of external aggressionson the skin also include, but are not limited to, loss of cellviability, loss or alteration of cell functions, and changes in geneand/or protein expression.

As used herein, “safe and effective amount” means an amount of compoundor composition (e.g., the Feverfew extract) sufficient to significantlyinduce a positive modification in the condition to be regulated ortreated, but low enough to avoid serious side effects. The safe andeffective amount of the compound or composition will vary with theparticular condition being treated, the age and physical condition ofthe end user, the severity of the condition being treated/prevented, theduration of the treatment, the nature of concurrent therapy, thespecific compound or composition employed, the particularcosmetically-acceptable topical carrier utilized, and like factors.

It furthermore has been found that the combined use of Feverfew extractin combination with Ginkgo biloba enhances the naturalskin-detoxification mechanism and formulations containing thiscombination can be used for this purpose. Skin radiance is improved byapplying this combination to the skin resulting in protecting anddetoxifying effects helping better the skin to counteract toxins. Theinvention also relates to the treatment of external aggressions in skinincluding by using a cosmetical formulation as defined herein.

The invention is further illustrated by the following examples.

EXAMPLES Example 1

An aqueous phase is made starting from the required amount of water andadding under stirring all water-soluble components. Separately an oilphase is made by mixing all oil components. Then the oily phase is addedto the aqueous phase while stirring at increased temperature (75-80°C.). The whole is allowed to stir for a while to allow forming a stableemulsion. The whole is allowed to cool to ambient temperature whereuponthe further components (butylene glycol, cyclopentasiloxane,dimethicone, Gingko extract, NaOH, perfume) are added under stirring.The Gingko extract used in this and the following example is extract asprepared in the examples of EP-A-977619. The feverfew extract used inthis and the following example is extract substantially free ofα-unsaturated γ-lactones as described in WO-00/74699. INCI Name % (w/w)Aqua 74.2306 Disodium EDTA 0.02 Panthenol 75%/Aqua 25% 0.70 Glycerin3.00 C10-30 Alkyl Acrylate Crosspolymer 0.20 Chrysanthemum Parthenium0.10 Cetyl alcohol 0.80 Isononyl Isononanoate 4.00 Tocopheryl acetate0.60 Isopropylparaben 40%/isobutylparaben 30%/ 0.80 Butylparaben 30%Glyceryl Stearate 50%/PEG-100 Stearate 50% 1.80 Butyrospermum Parkii2.00 Hexyldecyl stearate 1.00 Ceteth-20 5%/Cetyl Alcohol 40%/GlycerylStearate 1.00 32.5%/PEG-75 Stearate 17.5%/Steareth-20.5% C13-14isoparaffin 15-20%/Laureth-7 1.00 3-8%/Polyacrylamide 35-45%/Aqua 47-27%Butylene glycol 3.50 Cyclopentasiloxane 4.00 Dimethicone 1.00 GingkoBiloba 0.05 Sodium Hydroxide 0.0494 Parfum 0.15 Total 100.00

Example 2

This formulation is made following the same procedure as described inExample 1. INCI Name % (w/w) Aqua 77.04 Disodium EDTA 0.006 Panthenol75%/Aqua 25% 0.70 Glycerin 5.00 Aqua 46%/DMDM Hydantoin 54% 0.26 C10-30Alkyl Acrylate Crosspolymer 0.10 Chrysanthemum Parthenium 0.10 SodiumHydroxide 20%/Aqua 80% 0.06 Cetyl alcohol 3.50 Caprilic/CapricTriglyceride 2.00 Hydrogenated Palm Glycerides Citrate 0.630-40%/Tocopherol 50-70% Iodopropynyl Butylcarbamate 10%/PEG-4 10%/ 0.10PEG-4 Laurate 40%/PEG-4 Dilaurate. Glyceryl Stearate 50%/PEG-100Stearate 50% 3.00 Butyrospermum Parkii 0.50 Sodium acrylate/SodiumAcryloyldimethyl Taurate 0.80 Copolymer 25%/Isohexadecane20%/Polysorbate 80 7%/Aqua 48% Cyclopentasiloxane 4.50 Dimethicone 1.50Gingko Biloba 0.01 Propylene Glycol 0.10 Disodium EDTA 2.00 Parfum 0.10Total 100.00

1. A cosmetic formulation comprising feverfew extract and Gingko Bilobaextract.
 2. A cosmetic formulation according to claim 1, wherein saidcomposition comprises: (a) from 0.01% to 5% of said feverfew extract;and (b) from 0.005% to 1% of said Gingko biloba extract.
 3. A cosmeticformulation according to claim 1, wherein the w/w ratio between thetotal amount of Feverfew extracts and the total amount of Gingko bilobaextracts is in the range of from 1000:1 to 1:100.
 4. A cosmeticformulation according to claim 1, wherein the feverfew extractsubstantially free of α-unsaturated γ-lactone
 5. A cosmetic formulationaccording to claim 1, wherein the Gingko biloba extract has a content ofterpene derivatives with a value of less than about 3% w/w of drymatter.
 6. A cosmetic formulation according to claim 5 wherein theconcentration of proanthocyanidins in said Gingko biloba is preferablyless than 5% w/w of the dry extract.
 7. A method of maintaining orimproving skin radiance, said method comprising the topical applicationof the cosmetic formulation of claim 1 to said skin.
 8. A cosmeticformulation according to claim 2, wherein the w/w ratio between thetotal amount of Feverfew extracts and the total amount of Gingko bilobaextracts is in the range of from 1000:1 to 1:100.
 9. A cosmeticformulation according to claim 2, wherein the feverfew extractsubstantially free of α-unsaturated γ-lactone
 10. A cosmetic formulationaccording to claim 2, wherein the Gingko biloba extract has a content ofterpene derivatives with a value of less than about 3% w/w of drymatter.
 11. A cosmetic formulation according to claim 5 wherein in theGingko biloba extract the concentration of proanthocyanidins ispreferably less than 5% w/w of the dry extract.
 12. A method accordingto claim 7, wherein said composition comprises: (a) from 0.01% to 5% ofsaid feverfew extract; and (b) from 0.005% to 1% of said Gingko bilobaextract.
 13. A method according to claim 7, wherein the w/w ratiobetween the total amount of Feverfew extracts and the total amount ofGingko biloba extracts is in the range of from 1000:1 to 1:100.
 14. Amethod according to claim 7, wherein the feverfew extract substantiallyfree of α-unsaturated γ-lactone
 15. A method according to claim 7,wherein the Gingko biloba extract has a content of terpene derivativeswith a value of less than about 3% w/w of dry matter.
 16. A methodaccording to claim 7, wherein in the Gingko biloba extract theconcentration of proanthocyanidins is preferably less than 5% w/w of thedry extract.
 17. A method according to claim 7, wherein the w/w ratiobetween the total amount of Feverfew extracts and the total amount ofGingko biloba extracts is in the range of from 1000:1 to 1:100.
 18. Amethod according to claim 7, wherein the feverfew extract substantiallyfree of α-unsaturated γ-lactone
 19. A method according to claim 7,wherein the Gingko biloba extract has a content of terpene derivativeswith a value of less than about 3% w/w of dry matter.
 20. A methodaccording to claim 7, wherein in the Gingko biloba extract theconcentration of proanthocyanidins is preferably less than 5% w/w of thedry extract.